AXIOS Stent With Electrocautery Enhanced Delivery System



Status:Completed
Conditions:Endocrine
Therapuetic Areas:Endocrinology
Healthy:No
Age Range:18 - 75
Updated:4/21/2016
Start Date:June 2014
End Date:March 2015

Use our guide to learn which trials are right for you!

The purpose of this study is to demonstrate the safety and effectiveness of the AXIOS Stent
with Electrocautery Enhanced Delivery System for endoscopic transenteric drainage of
pancreatic pseudocysts.


Inclusion Criteria:

1. Age between 18 and 75 years old, male or female

2. Eligible for endoscopic intervention

3. Acceptable candidate for endoscopic transluminal pancreatic pseudocyst drainage

4. Symptomatic pancreatic pseudocyst having the following characteristics:

- Greater or equal to 6 cm in diameter (based upon the maximum cross-sectional
area in the CT scan or transabdominal ultrasound).

- Adherent to bowel wall, and

- ≥70% fluid content

5. Patient understands the study requirements and the treatment procedures and provides
written Informed Consent.

6. Patient is willing to comply with all specified follow-up evaluations, including
willingness to undergo a pre/post CT imaging study.

Exclusion Criteria:

1. The fluid collection to be drained is an immature pseudocyst

2. The fluid collection to be drained is a cystic neoplasm

3. The fluid collection to be drained is a pseudoaneurysm

4. The fluid collection to be drained is a duplication cyst

5. The fluid collection to be drained is a non-inflammatory fluid collection

6. There is more than one pseudocyst requiring drainage

7. Abnormal coagulation:

- INR > 1.5 and not correctable

- presence of a bleeding disorder

- platelets < 50,000/mm3

8. Altered anatomy that precludes the physician's ability to deliver the stent (decision
on a case by case basis).

9. Intervening gastric varices or vessels within a one centimeter radius of the needle
(visible using endoscopy or endoscopic ultrasound)

10. Any prior true anaphylactic reaction to contrast agents, nitinol (nickel titanium),
silicone or any other materials contacting the patient.

11. Female of childbearing potential with a positive pregnancy test prior to the
procedure or intends to become pregnant during the study.

12. Currently participating in another investigational drug of device study that has not
completed the primary endpoint or that clinically interferes with the endpoints of
this study.
We found this trial at
8
sites
201 Dowman Dr
Atlanta, Georgia 30303
(404) 727-6123
Emory University Emory University, recognized internationally for its outstanding liberal artscolleges, graduate and professional schools,...
?
mi
from
Atlanta, GA
Click here to add this to my saved trials
3400 N Charles St
Baltimore, Maryland 21205
410-516-8000
Johns Hopkins University The Johns Hopkins University opened in 1876, with the inauguration of its...
?
mi
from
Baltimore, MD
Click here to add this to my saved trials
Jacksonville, Florida 32207
?
mi
from
Jacksonville, FL
Click here to add this to my saved trials
13001 E. 17th Pl
Aurora, Colorado 80045
303-724-5000
University of Colorado Denver The University of Colorado Denver | Anschutz Medical Campus provides a...
?
mi
from
Aurora, CO
Click here to add this to my saved trials
5841 S Maryland Ave
Chicago, Illinois 60637
(773) 702-1000
University of Chicago Medical Center The University of Chicago Medicine has been at the forefront...
?
mi
from
Chicago, IL
Click here to add this to my saved trials
601 E Rollins St
Orlando, Florida 32803
(407) 303-5600
Florida Hospital Florida Hospital is one of the country
?
mi
from
Orlando, FL
Click here to add this to my saved trials
1020 Walnut St
Philadelphia, Pennsylvania 19107
(215) 955-6000
Thomas Jefferson University We are dedicated to the health sciences and committed to educating professionals,...
?
mi
from
Philadelphia, PA
Click here to add this to my saved trials
St. Louis, Missouri 63110
?
mi
from
St. Louis, MO
Click here to add this to my saved trials